JP2008523041A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008523041A5 JP2008523041A5 JP2007544984A JP2007544984A JP2008523041A5 JP 2008523041 A5 JP2008523041 A5 JP 2008523041A5 JP 2007544984 A JP2007544984 A JP 2007544984A JP 2007544984 A JP2007544984 A JP 2007544984A JP 2008523041 A5 JP2008523041 A5 JP 2008523041A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- amino
- independently selected
- alkoxy
- imidazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 65
- -1 nitro, amino Chemical group 0.000 claims 42
- 125000003545 alkoxy group Chemical group 0.000 claims 31
- 229910052760 oxygen Inorganic materials 0.000 claims 31
- 229910052717 sulfur Inorganic materials 0.000 claims 29
- 125000000623 heterocyclic group Chemical group 0.000 claims 26
- 125000005842 heteroatom Chemical group 0.000 claims 22
- 125000003118 aryl group Chemical group 0.000 claims 18
- 125000005843 halogen group Chemical group 0.000 claims 17
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 16
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical class 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims 12
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 229920006395 saturated elastomer Polymers 0.000 claims 10
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- 125000004043 oxo group Chemical group O=* 0.000 claims 9
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 6
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 5
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 4
- 125000000335 thiazolyl group Chemical group 0.000 claims 4
- 125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical group 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000004104 aryloxy group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 208000036626 Mental retardation Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 2
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 125000005874 benzothiadiazolyl group Chemical group 0.000 claims 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 claims 2
- 125000004598 dihydrobenzofuryl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 claims 2
- 125000005434 dihydrobenzoxazinyl group Chemical group O1N(CCC2=C1C=CC=C2)* 0.000 claims 2
- 125000005435 dihydrobenzoxazolyl group Chemical group O1C(NC2=C1C=CC=C2)* 0.000 claims 2
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 2
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims 2
- 125000004609 dihydroquinazolinyl group Chemical group N1(CN=CC2=CC=CC=C12)* 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- AWTXQEUYEIEIGL-QHCPKHFHSA-N n-[(1s)-1-[5-(2-methoxyquinolin-3-yl)-1h-imidazol-2-yl]-7-oxononyl]-1-methylazetidine-3-carboxamide Chemical compound N([C@@H](CCCCCC(=O)CC)C=1NC(=CN=1)C=1C(=NC2=CC=CC=C2C=1)OC)C(=O)C1CN(C)C1 AWTXQEUYEIEIGL-QHCPKHFHSA-N 0.000 claims 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 125000005886 tetrahydrobenzothienyl group Chemical group 0.000 claims 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 2
- RGDYYZABWAEBLN-UQIIZPHYSA-N (7s)-7-(benzylcarbamoylamino)-n-methyl-7-(5-naphthalen-2-yl-1h-imidazol-3-ium-2-yl)heptanamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.N([C@@H](CCCCCC(=O)NC)C1=[NH+]C=C(N1)C=1C=C2C=CC=CC2=CC=1)C(=O)NCC1=CC=CC=C1 RGDYYZABWAEBLN-UQIIZPHYSA-N 0.000 claims 1
- FMYSDZLRMFEERJ-FYZYNONXSA-N (7s)-7-(dimethylsulfamoylamino)-7-(5-naphthalen-2-yl-1h-imidazol-1-ium-2-yl)heptanoic acid;2,2,2-trifluoroacetate Chemical compound OC(=O)C(F)(F)F.N1C([C@H](CCCCCC(O)=O)NS(=O)(=O)N(C)C)=NC=C1C1=CC=C(C=CC=C2)C2=C1 FMYSDZLRMFEERJ-FYZYNONXSA-N 0.000 claims 1
- CJCMSDVKMMQSDZ-JCOPYZAKSA-N (7s)-7-[[2-(5-methoxy-2-methyl-1h-indol-3-yl)acetyl]amino]-7-(5-naphthalen-2-yl-1h-imidazol-1-ium-2-yl)heptanamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.C1=CC=CC2=CC(C=3NC(=[NH+]C=3)[C@H](CCCCCC(N)=O)NC(=O)CC3=C(C)NC4=CC=C(C=C43)OC)=CC=C21 CJCMSDVKMMQSDZ-JCOPYZAKSA-N 0.000 claims 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- KIOOMPMDNMDGIR-ASMAMLKCSA-N 1-methyl-n-[(1s)-1-(5-naphthalen-2-yl-1h-imidazol-3-ium-2-yl)-7-oxononyl]azetidin-1-ium-3-carboxamide;dichloride Chemical compound [Cl-].[Cl-].N([C@@H](CCCCCC(=O)CC)C1=[NH+]C=C(N1)C=1C=C2C=CC=CC2=CC=1)C(=O)C1C[NH+](C)C1 KIOOMPMDNMDGIR-ASMAMLKCSA-N 0.000 claims 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims 1
- FZDSJCLWCBJIRR-BDQAORGHSA-N 2,2,2-trifluoroacetate;2,2,2-trifluoro-n-[(1s)-1-(5-naphthalen-2-yl-1h-imidazol-1-ium-2-yl)-7-oxononyl]acetamide Chemical compound [O-]C(=O)C(F)(F)F.[NH2+]1C([C@@H](NC(=O)C(F)(F)F)CCCCCC(=O)CC)=NC=C1C1=CC=C(C=CC=C2)C2=C1 FZDSJCLWCBJIRR-BDQAORGHSA-N 0.000 claims 1
- AVBZOBRNOPYNDI-CZCBIWLKSA-N 2-(5-methoxy-2-methyl-1h-indol-3-yl)-n-[(1s)-1-(5-naphthalen-2-yl-1h-imidazol-1-ium-2-yl)-7-oxo-8-sulfamoyloctyl]acetamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.C1=CC=CC2=CC(C3=CN=C([NH2+]3)[C@H](CCCCCC(=O)CS(N)(=O)=O)NC(=O)CC3=C(C)NC4=CC=C(C=C43)OC)=CC=C21 AVBZOBRNOPYNDI-CZCBIWLKSA-N 0.000 claims 1
- SFMUMRDHCDHKHH-JMAPEOGHSA-N 2-(5-methoxy-2-methyl-1h-indol-3-yl)-n-[(1s)-7-oxo-1-(5-phenyl-1h-imidazol-1-ium-2-yl)undecyl]acetamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.[NH2+]1C([C@@H](NC(=O)CC=2C3=CC(OC)=CC=C3NC=2C)CCCCCC(=O)CCCC)=NC=C1C1=CC=CC=C1 SFMUMRDHCDHKHH-JMAPEOGHSA-N 0.000 claims 1
- GTYARFWDYKVLKC-CZCBIWLKSA-N 2-(5-methoxy-2-methyl-1h-indol-3-yl)-n-[(1s)-7-oxo-1-[5-(4-pyrazol-1-ylphenyl)-1h-imidazol-2-yl]nonyl]acetamide;2,2,2-trifluoroacetic acid Chemical compound [O-]C(=O)C(F)(F)F.C=1[NH+]=C([C@@H](NC(=O)CC=2C3=CC(OC)=CC=C3NC=2C)CCCCCC(=O)CC)NC=1C(C=C1)=CC=C1N1C=CC=N1 GTYARFWDYKVLKC-CZCBIWLKSA-N 0.000 claims 1
- AJNVIMUEYAYHCK-DTZDFASDSA-N 2-(5-methoxy-2-methyl-1h-indol-3-yl)-n-[(1s)-8-methylsulfinyl-1-(5-naphthalen-2-yl-1h-imidazol-1-ium-2-yl)-7-oxooctyl]acetamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.C1=CC=CC2=CC(C3=CN=C([NH2+]3)[C@H](CCCCCC(=O)CS(C)=O)NC(=O)CC3=C(C)NC4=CC=C(C=C43)OC)=CC=C21 AJNVIMUEYAYHCK-DTZDFASDSA-N 0.000 claims 1
- POMSFCYABFGOGX-YNMZEGNTSA-N 2-(5-methoxy-2-methyl-1h-indol-3-yl)-n-[(1s)-8-methylsulfonyl-1-(5-naphthalen-2-yl-1h-imidazol-1-ium-2-yl)-7-oxooctyl]acetamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.C1=CC=CC2=CC(C3=CN=C([NH2+]3)[C@H](CCCCCC(=O)CS(C)(=O)=O)NC(=O)CC3=C(C)NC4=CC=C(C=C43)OC)=CC=C21 POMSFCYABFGOGX-YNMZEGNTSA-N 0.000 claims 1
- LTMWFWAITCDTHV-JMAPEOGHSA-N 2-(5-methoxy-2-methyl-1h-indol-3-yl)-n-[(1s)-9-methyl-7-oxo-1-(5-phenyl-1h-imidazol-1-ium-2-yl)decyl]acetamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.[NH2+]1C([C@H](CCCCCC(=O)CC(C)C)NC(=O)CC2=C(C)NC3=CC=C(C=C32)OC)=NC=C1C1=CC=CC=C1 LTMWFWAITCDTHV-JMAPEOGHSA-N 0.000 claims 1
- MTPRQJBMGXLBFQ-BDQAORGHSA-N 2-[[(1s)-1-(5-naphthalen-2-yl-1h-imidazol-1-ium-2-yl)-7-oxononyl]amino]-2-oxoacetic acid;2,2,2-trifluoroacetate Chemical compound OC(=O)C(F)(F)F.N1C([C@@H](NC(=O)C(O)=O)CCCCCC(=O)CC)=NC=C1C1=CC=C(C=CC=C2)C2=C1 MTPRQJBMGXLBFQ-BDQAORGHSA-N 0.000 claims 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 claims 1
- XVGPMJIRIRTPRC-JIDHJSLPSA-N 2-morpholin-4-yl-n-[(1s)-1-(5-naphthalen-2-yl-1h-imidazol-1-ium-2-yl)-7-oxononyl]-2-oxoacetamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.N([C@@H](CCCCCC(=O)CC)C=1[NH2+]C(=CN=1)C=1C=C2C=CC=CC2=CC=1)C(=O)C(=O)N1CCOCC1 XVGPMJIRIRTPRC-JIDHJSLPSA-N 0.000 claims 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 1
- 102000003964 Histone deacetylase Human genes 0.000 claims 1
- 108090000353 Histone deacetylase Proteins 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 241000199911 Peridinium Species 0.000 claims 1
- SFFZKSDMUQBXKC-UHFFFAOYSA-N [Cl-].[Cl-].[Cl-].[NH+]1=CC=CC2=CC=CC=C12.[NH+]1=CC=CC2=CC=CC=C12.[NH+]1=CC=CC2=CC=CC=C12 Chemical compound [Cl-].[Cl-].[Cl-].[NH+]1=CC=CC2=CC=CC=C12.[NH+]1=CC=CC2=CC=CC=C12.[NH+]1=CC=CC2=CC=CC=C12 SFFZKSDMUQBXKC-UHFFFAOYSA-N 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- VPMNJMINCAIGEK-ASMAMLKCSA-N dimethyl-[3-[[(1s)-1-(5-naphthalen-2-yl-1h-imidazol-3-ium-2-yl)-7-oxononyl]amino]-3-oxopropyl]azanium;dichloride Chemical compound [Cl-].[Cl-].[NH+]1=C([C@@H](NC(=O)CC[NH+](C)C)CCCCCC(=O)CC)NC(C=2C=C3C=CC=CC3=CC=2)=C1 VPMNJMINCAIGEK-ASMAMLKCSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 1
- LGKVIMHMYLBJIV-JHGYPSGKSA-N methyl (e)-3-[2-[1-[[2-(5-methoxy-2-methyl-1h-indol-3-yl)acetyl]amino]-7-oxononyl]-1h-imidazol-1-ium-5-yl]prop-2-enoate;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CC=1NC2=CC=C(OC)C=C2C=1CC(=O)NC(CCCCCC(=O)CC)C1=NC=C(\C=C\C(=O)OC)[NH2+]1 LGKVIMHMYLBJIV-JHGYPSGKSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- PHFSQRBJHJIHLO-BQAIUKQQSA-N n-[(1s)-1-(5-acetyl-1h-imidazol-1-ium-2-yl)-7-oxononyl]-2-(5-methoxy-2-methyl-1h-indol-3-yl)acetamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.C1([C@@H](NC(=O)CC=2C3=CC(OC)=CC=C3NC=2C)CCCCCC(=O)CC)=NC=C(C(C)=O)[NH2+]1 PHFSQRBJHJIHLO-BQAIUKQQSA-N 0.000 claims 1
- COLQAVHFRHNFOB-YCBFMBTMSA-N n-[(1s)-1-(5-cyclohexyl-1h-imidazol-1-ium-2-yl)-7-oxononyl]-2-(5-methoxy-2-methyl-1h-indol-3-yl)acetamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.[NH2+]1C([C@@H](NC(=O)CC=2C3=CC(OC)=CC=C3NC=2C)CCCCCC(=O)CC)=NC=C1C1CCCCC1 COLQAVHFRHNFOB-YCBFMBTMSA-N 0.000 claims 1
- OKZJMZLPCYPWPZ-QHCPKHFHSA-N n-[(1s)-1-(5-naphthalen-2-yl-1,3,4-oxadiazol-2-yl)-5-oxoheptyl]-1-azabicyclo[2.2.2]octane-4-carboxamide Chemical compound C1=CC=CC2=CC(C3=NN=C(O3)[C@@H](NC(=O)C34CCN(CC3)CC4)CCCC(=O)CC)=CC=C21 OKZJMZLPCYPWPZ-QHCPKHFHSA-N 0.000 claims 1
- FKQQWYRZPCKSCR-YNMZEGNTSA-N n-[(1s)-7-(furan-2-yl)-1-(5-naphthalen-2-yl-1h-imidazol-1-ium-2-yl)-7-oxoheptyl]-2-(5-methoxy-2-methyl-1h-indol-3-yl)acetamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.C([C@H](NC(=O)CC1=C(C)NC2=CC=C(C=C21)OC)C=1[NH2+]C(=CN=1)C=1C=C2C=CC=CC2=CC=1)CCCCC(=O)C1=CC=CO1 FKQQWYRZPCKSCR-YNMZEGNTSA-N 0.000 claims 1
- NNGBMRDHXMUILU-LEUNPYLKSA-N n-[(1s)-7-(methylamino)-1-(5-naphthalen-2-yl-1h-imidazol-1-ium-2-yl)-7-oxoheptyl]-1-pyridin-2-ylpiperidine-3-carboxamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.N([C@@H](CCCCCC(=O)NC)C=1[NH2+]C(=CN=1)C=1C=C2C=CC=CC2=CC=1)C(=O)C(C1)CCCN1C1=CC=CC=N1 NNGBMRDHXMUILU-LEUNPYLKSA-N 0.000 claims 1
- YVLFOSUHKSCOSF-YCBFMBTMSA-N n-[(1s)-7-cyclopropyl-7-oxo-1-(5-phenyl-1h-imidazol-1-ium-2-yl)heptyl]-2-(5-methoxy-2-methyl-1h-indol-3-yl)acetamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.C([C@H](NC(=O)CC1=C(C)NC2=CC=C(C=C21)OC)C=1[NH2+]C(=CN=1)C=1C=CC=CC=1)CCCCC(=O)C1CC1 YVLFOSUHKSCOSF-YCBFMBTMSA-N 0.000 claims 1
- HOQONYGWPYIJTF-SNYZSRNZSA-N n-[(1s)-8-hydroxy-7-oxo-1-(5-phenyl-1h-imidazol-1-ium-2-yl)octyl]-2-(5-methoxy-2-methyl-1h-indol-3-yl)acetamide;2,2,2-trifluoroacetate Chemical compound OC(=O)C(F)(F)F.N1C([C@H](CCCCCC(=O)CO)NC(=O)CC2=C(C)NC3=CC=C(C=C32)OC)=NC=C1C1=CC=CC=C1 HOQONYGWPYIJTF-SNYZSRNZSA-N 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 229930195734 saturated hydrocarbon Natural products 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 claims 1
- 150000003892 tartrate salts Chemical class 0.000 claims 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0427138A GB0427138D0 (en) | 2004-12-10 | 2004-12-10 | Therapeutic compounds |
| GB0427138.3 | 2004-12-10 | ||
| GB0516435.5 | 2005-08-11 | ||
| GB0516435A GB0516435D0 (en) | 2005-08-11 | 2005-08-11 | Therapeutic compounds |
| PCT/GB2005/004743 WO2006061638A2 (en) | 2004-12-10 | 2005-12-09 | Heterocycle derivatives as histone deacetylase (hdac) inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012251740A Division JP5878859B2 (ja) | 2004-12-10 | 2012-11-16 | ヒストンデアセチラーゼ（ｈｄａｃ）阻害剤としての複素環誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008523041A JP2008523041A (ja) | 2008-07-03 |
| JP2008523041A5 true JP2008523041A5 (enExample) | 2010-12-02 |
| JP5197014B2 JP5197014B2 (ja) | 2013-05-15 |
Family
ID=36424637
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007544984A Expired - Lifetime JP5197014B2 (ja) | 2004-12-10 | 2005-12-09 | ヒストンデアセチラーゼ（ｈｄａｃ）阻害剤としての複素環誘導体 |
| JP2012251740A Expired - Lifetime JP5878859B2 (ja) | 2004-12-10 | 2012-11-16 | ヒストンデアセチラーゼ（ｈｄａｃ）阻害剤としての複素環誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012251740A Expired - Lifetime JP5878859B2 (ja) | 2004-12-10 | 2012-11-16 | ヒストンデアセチラーゼ（ｈｄａｃ）阻害剤としての複素環誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7863294B2 (enExample) |
| EP (1) | EP1828171B1 (enExample) |
| JP (2) | JP5197014B2 (enExample) |
| AU (1) | AU2005313108B2 (enExample) |
| CA (1) | CA2590811C (enExample) |
| ES (1) | ES2462341T3 (enExample) |
| WO (1) | WO2006061638A2 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005070020A2 (en) | 2004-01-23 | 2005-08-04 | The Regents Of The University Of Colorado | Gefitinib sensitivity-related gene expression and products and methods related thereto |
| ES2537631T3 (es) | 2004-05-27 | 2015-06-10 | The Regents Of The University Of Colorado | Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer |
| GB0518237D0 (en) | 2005-09-07 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| GB0522130D0 (en) * | 2005-10-31 | 2005-12-07 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| WO2007070826A1 (en) | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
| WO2007070816A2 (en) * | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Thiophene derivatives as factor xia inhibitors |
| GB0526107D0 (en) * | 2005-12-22 | 2006-02-01 | Angeletti P Ist Richerche Bio | Therapeutic Compounds |
| WO2009042646A1 (en) * | 2007-09-24 | 2009-04-02 | Curis, Inc. | Anti-proliferative agents |
| RU2011121655A (ru) * | 2008-10-29 | 2012-12-10 | Сертрис Фармасьютикалз, Инк. | Производные пиридина, бициклические производные пиридина и родственные аналоги в качестве модуляторов сиртуина |
| GB0900484D0 (en) | 2009-01-13 | 2009-02-11 | Angeletti P Ist Richerche Bio | Therapeutic agent |
| GB0916608D0 (en) | 2009-09-22 | 2009-11-04 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US9169234B2 (en) | 2009-10-15 | 2015-10-27 | Children's Medical Center Corporation | Sepiapterin reductase inhibitors for the treatment of pain |
| AU2010313487A1 (en) | 2009-10-26 | 2012-05-24 | Emkinetics, Inc. | Method and apparatus for electromagnetic stimulation of nerve, muscle, and body tissues |
| JP2013517279A (ja) * | 2010-01-13 | 2013-05-16 | テンペロ、ファーマシューティカルズ、インコーポレイテッド | 化合物及び方法 |
| US8981084B2 (en) | 2010-01-13 | 2015-03-17 | Tempero Pharmaceuticals, Inc. | Oxadiazole HDAC inhibitors |
| KR101781663B1 (ko) | 2010-01-13 | 2017-09-25 | 템페로 파마슈티칼즈, 인크. | 히스톤 데아세틸라제 효소를 억제하기 위한 화합물 및 이를 제조하는 방법 |
| WO2011130163A1 (en) * | 2010-04-12 | 2011-10-20 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| MX2013002011A (es) * | 2010-08-20 | 2013-03-25 | Gruenenthal Gmbh | Derivados ciclicos de carboxamida y urea sustituidos como ligandos del receptor vainiloide. |
| MX2013005008A (es) * | 2010-11-10 | 2013-08-01 | Gruenenthal Gmbh | Derivados de carboxamida y urea heteroaromaticos sustituidos como ligandos del receptor vanilloide. |
| WO2013006408A1 (en) * | 2011-07-01 | 2013-01-10 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| WO2013005798A1 (ja) * | 2011-07-06 | 2013-01-10 | 持田製薬株式会社 | 新規含窒素複素環誘導体 |
| WO2013009830A1 (en) * | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| WO2013009812A1 (en) * | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc | Methods of treatment |
| WO2013009827A1 (en) * | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| WO2013009810A1 (en) * | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| ITRM20120405A1 (it) * | 2012-08-09 | 2014-02-10 | C N C C S Scarl Collezione Naziona Le Dei Compost | Compounds for use in the treatment of disorders that are ameliorated by inhibition of hdac |
| CA2882306A1 (en) | 2012-08-24 | 2014-02-27 | Board Of Regents, The University Of Texas System | Heterocyclic modulators of hif activity for treatment of disease |
| ITRM20120530A1 (it) | 2012-10-31 | 2014-05-01 | C N C C S S C A R L Collezione Na Zionale Dei Co | Compounds for use in the treatment of parasitic diseases |
| CN103588761B (zh) * | 2013-10-22 | 2015-05-27 | 湖南大学 | N-[1-(苯并呋喃-5-基)-2-氧代乙基]苯并吡喃-4-酰胺的制备与应用 |
| US10053434B2 (en) | 2015-05-07 | 2018-08-21 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| EP3291809B1 (en) | 2015-05-07 | 2021-08-25 | CHDI Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| WO2018094005A1 (en) * | 2016-11-16 | 2018-05-24 | The General Hospital Corporation | Myeloperoxidase imaging agents |
| CN107226791B (zh) * | 2017-06-13 | 2020-07-10 | 贵州医科大学 | 氮氧化物作为新型组蛋白去乙酰化酶抑制剂的抗肿瘤应用 |
| US11731952B2 (en) | 2017-08-31 | 2023-08-22 | Musc Foundation For Research Development | Indene derivatives and uses thereof |
| EP3829559A4 (en) * | 2018-08-01 | 2022-03-23 | Merck Sharp & Dohme Corp. | HISTONE-DEACETYLASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF HIV INFECTION |
| WO2020096916A2 (en) * | 2018-11-08 | 2020-05-14 | Merck Sharp & Dohme Corp. | Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection |
| WO2020150091A1 (en) * | 2019-01-15 | 2020-07-23 | Merck Sharp & Dohme Corp. | Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection |
| WO2020190827A1 (en) | 2019-03-21 | 2020-09-24 | Merck Sharp & Dohme Corp. | Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection |
| CN110776521A (zh) * | 2019-10-24 | 2020-02-11 | 秦源生物医药科技(上海)有限公司 | 一种1,2,4-三唑-1,3,4-噻二唑类化合物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0946587A2 (en) * | 1996-12-16 | 1999-10-06 | Fujisawa Pharmaceutical Co., Ltd. | New amide compounds |
| DE69921124T2 (de) * | 1998-06-12 | 2005-11-10 | Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. | Imidazolderivate und ihre verwendung als somatostatin rezeptorliganden |
| TWI292316B (en) * | 1999-10-11 | 2008-01-11 | Sod Conseils Rech Applic | Pharmaceutical composition of thiazole derivatives intended to inhibit mao and/or lipidic peroxidation and/or to act as modulators of sodium channels and the use thereof |
| ES2282275T3 (es) | 2000-08-01 | 2007-10-16 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derivados de imidazolilo. |
| AU2003900608A0 (en) * | 2003-02-11 | 2003-02-27 | Fujisawa Pharmaceutical Co., Ltd. | Hdac inhibitor |
| US20040186151A1 (en) * | 2003-02-12 | 2004-09-23 | Mjalli Adnan M.M. | Substituted azole derivatives as therapeutic agents |
| EP1768955A1 (en) | 2004-07-12 | 2007-04-04 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Amide derivatives as inhibitors of histone deacetylase |
| CN101133024A (zh) | 2004-07-12 | 2008-02-27 | P.安杰莱蒂分子生物学研究所 | 作为组蛋白脱乙酰酶抑制剂的酰胺衍生物 |
| GB0522130D0 (en) | 2005-10-31 | 2005-12-07 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| GB0526107D0 (en) | 2005-12-22 | 2006-02-01 | Angeletti P Ist Richerche Bio | Therapeutic Compounds |
-
2005
- 2005-12-09 EP EP05818301.3A patent/EP1828171B1/en not_active Expired - Lifetime
- 2005-12-09 WO PCT/GB2005/004743 patent/WO2006061638A2/en not_active Ceased
- 2005-12-09 CA CA2590811A patent/CA2590811C/en not_active Expired - Lifetime
- 2005-12-09 JP JP2007544984A patent/JP5197014B2/ja not_active Expired - Lifetime
- 2005-12-09 AU AU2005313108A patent/AU2005313108B2/en not_active Expired
- 2005-12-09 US US11/792,294 patent/US7863294B2/en active Active
- 2005-12-09 ES ES05818301.3T patent/ES2462341T3/es not_active Expired - Lifetime
-
2012
- 2012-11-16 JP JP2012251740A patent/JP5878859B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008523041A5 (enExample) | ||
| TWI579284B (zh) | 咪唑并吡咯啶酮化合物 | |
| CA2934137C (en) | Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments | |
| JP2010533158A5 (enExample) | ||
| JP2012525431A5 (enExample) | ||
| ES2967119T3 (es) | Compuestos inhibidores de metaloenzimas | |
| KR101363090B1 (ko) | 아자비시클로 헥산 유도체의 용도 | |
| JP2017508766A5 (enExample) | ||
| JP2007505933A5 (enExample) | ||
| JP2016512511A5 (enExample) | ||
| JP2006504658A5 (enExample) | ||
| EP3458443A1 (en) | Aromatic sulfonamide derivatives | |
| JP2011503166A5 (enExample) | ||
| CN103096718A (zh) | 可溶性鸟苷酸环化酶活化剂 | |
| RU2012139828A (ru) | Производные пиразолопиперидина в качестве ингибиторов nadph-оксидазы | |
| JP2017505762A5 (enExample) | ||
| MX2010013399A (es) | Nuevos compuestos de 1,2,4-oxadiazol y sus metodos de uso. | |
| CA3071760A1 (en) | Combination of atr kinase inhibitors and pd-1/pd-l1 inhibitors | |
| RU2016141645A (ru) | ИНГИБИТОРЫ TrkA КИНАЗЫ, ОСНОВАННЫЕ НА НИХ КОМПОЗИЦИИ И СПОСОБЫ | |
| JP2013515032A5 (enExample) | ||
| WO2023212240A1 (en) | Compounds for inhibiting kif18a | |
| IL205501A (en) | Preparation of preparations for the treatment of arthritis | |
| EP3817736A1 (en) | Pikfyve inhibitors | |
| RU2009123525A (ru) | ПРОИЗВОДНЫЕ 5-СУЛЬФАНИЛМЕТИЛ[1,2,4}ТРИАЗОЛ[1,5-а]ПИРИМИДИН-7-ОЛА В КАЧЕСТВЕ АНТАГОНИСТОВ CXCR2 | |
| JP2010536842A5 (enExample) |